NCT04629547View on ClinicalTrials.gov

Sleep Trial to Prevent Alzheimer's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
SleepAlzheimer Disease
Interventions
DRUG

Suvorexant 20 mg

Suvorexant 20mg will be taken nightly for 24 months.

DRUG

Placebo

Placebo will be taken nightly for 24 months.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Good Ventures
All Listed Sponsors
collaborator

Good Ventures

UNKNOWN

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04629547 - Sleep Trial to Prevent Alzheimer's Disease | Biotech Hunter | Biotech Hunter